This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Senate Bill 764 would prevent "pay to delay" agreements between pharmaceutical companies that delay the introduction of generic prescription drugs into the market.
Prescription drug prices were soaring. Angry policymakers swore they’d take action. Pharma giant Merck responded by promising to address the problem voluntarily, vowing to keep price increases under the overall rate of inflation.
Oregon U.S. Sen. Ron Wyden again blasted the Trump administration on Monday over its proposed drug pricing plan.